Issue 46 - Dec 13, 2019
  • “Call me Doctor”

    How women in oncology are fighting for cultural change

    A sense of foreboding descended on Narjust Duma as she sat at a presentation on drug-induced toxicities. The year was 2018, Duma was a 31-year-old second-year fellow at Mayo Clinic, and her discomfort stemmed from something other than the subject matter discussed.

  • Don’t call me Karen, Cheryl, Nancy, Reshma, Cornelia, Caryn, Sharon, … call me “Doctor.”

    Seven prominent women leaders in oncology—Karen Knudsen, Cheryl Willman, Reshma Jagsi, Nancy Davidson, Cornelia Ulrich, Caryn Lerman, and Sharon Stack—spoke with The Cancer Letter about their experiences with gender bias, implicit and explicit.

  • In Brief

    • Senate confirms Stephen Hahn as FDA commissioner
    • Moderate levels of alcohol consumption linked to higher risk of some cancers, NCI writes in JAMA
    • MSK to open David H. Koch Center for Cancer Care in January 2020
    • Thomas Jefferson University receives $70 million for new biomedical research building
    • Edmondo Robinson named chief digital innovation officer at Moffitt
    • Winship realigns its research programs to increase impact
  • TCCL Logo

  • Trials & Tribulations

    Nobel Prize Award: Impact of Clinical Care?

    On December 10, 2019, Dr. William G. Kaelin, Jr, Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza officially received the title of Nobel Laureate in Medicine.

  • Clinical Roundup

    • PD-1 inhibitor treatment prior to stem cell transplant is safe, effective in classic Hodgkin lymphoma
    • BMS’s liso-cel met primary, secondary endpoints in TRANSCEND NHL 001
    • Phase II KarMMa study of ide-cel in relapsed, refractory multiple myeloma meets ORR primary endpoint
    • Seattle Genetics announces positive OS, PFS, ORR for tucatinib in HER2+ breast cancer
    • ctDNA may help predict recurrence in patient with early triple-negative breast cancer
    • Extended follow-up phase III data underscore sustained efficacy and safety of Imbruvica in CLL
    • Phase III TOURMALINE-AL1 trial of Ninlaro in patients with amyloidosis didn’t meet one of two primary endpoints
    • Phase III SOPHIA study shows margetuximab didn’t reach significance for OS in HER2+ metastatic breast cancer
    • Keytruda improved OS in frontline metastatic NSCLC regardless of KRAS status
    • Venetoclax in reduced-intensity transplant conditioning regimen in high-risk myeloid cancers shows promise
  • Drugs & Targets

    • FDA issues draft guidance to foster pediatric oncology product development
    • FDA approves Avsola for same indications as Remicade
    • FDA grants Janssen’s BCMA CAR-T therapy JNJ-4528 Breakthrough Therapy Designation for multiple myeloma indication
Issue 45 - Dec 6, 2019
  • LOWY: Paylines are dropping because NCI is drawing more applicants who would’ve previously gone elsewhere

    After an examination of the causes of an avalanche of grant applications directed at NCI, institute officials found that new applications largely come from principal investigators  who are switching their research focus to cancer. No other  NIH institute or center faces such pressure.

  • NCI Director’s Report

    Sharpless reflects on his time at FDA: “The engine producing new cancer therapies and diagnostics is doing very well”

    The progress in cancer exceeds that of any other therapeutic area right now—at least as far as FDA is concerned, NCI Director Ned Sharpless said at a Dec. 3 joint meeting of the Board of Scientific Advisors and the National Cancer Advisory Board.

  • Senate committee votes 18-5 in support of Hahn, but questions his commitment to aggressive e-cigarette policy

    A Senate committee Dec. 3 cleared the path for Stephen M. Hahn to become the next FDA commissioner, though some Democratic and Republican senators voiced concerns that he wouldn’t take aggressive action to ban flavored e-cigarettes in this role.

  • AACR, Research!America urge Congress to pass spending bill with funding boost for health agencies

    The American Association for Cancer Research and Research!America are urging Congress to pass the FY20 appropriations bill by Dec. 20.

  • In Brief

    • Williams, Ingram, Mitchell to join President’s Cancer Panel
    • Belani named IASLC chief science officer
    • ACCC project focuses on multidisciplinary cutaneous squamous cell carcinoma care
    • Nimer receives Oscar de la Renta Endowed Chair in Cancer Research
    • Barker named chief strategy officer at USC Lawrence J. Ellison Institute for Transformative Medicine
    • Car named Agios chief scientific officer
    • Peterson receives $1.4M grant for innovative approach to attacking metastatic TNBC
    • Mt. Sinai receives $1M grant for prostate cancer research
  • Funding Opportunities

    ACS and Flatiron Health launch real-world data impact award

    The American Cancer Society and Flatiron Health launched a joint grant-making program that supports both organizations’ goals of accelerating cancer research and improving treatment and care options for patients.

  • TCCL Logo

  • Clinical Roundup

    • Study finds wide county-level variation in rates of surgery for early-stage lung cancer
    • Tecentriq + Avastin combination demonstrates improvement in OS, PFS in HCC
    • Alunbrig demonstrates reduced risk of death, disease progression in ALK+ NSCLC
    • Experimental targeted therapy may be better for repeat kidney cancer patients than FDA-approved counterpart, study finds
    • Duke researchers develop technique to visually depict how cancer cells grow and spread in colon tissue
  • Drugs & Targets

    • FDA approves Tecentriq + chemo as initial treatment metastatic non-squamous NSCLC indication
    • FDA approves FoundationOne CDx as a Companion Diagnostic for Piqray in new indication
    • FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication
    • FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements
    • China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication
    • Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication
  • NCI Trials

    NCI Trials for December 2019

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 44 - Nov 22, 2019